Is tumor necrosis factor-α monoclonal therapy with proactive therapeutic drug monitoring optimized for inflammatory bowel disease? Network meta-analysis

doi:10.4240/wjgs.v16.i2.571

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1833)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-2) series.

Item

Count

PDF

WORD

HTML

842

Figures (1-5)

154

Tables (1-2)

160

Sum=1220

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

130

Download

419

Sum=549

Feb 27, 2024 (publication date) through Nov 16, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Gastrointest Surg. Feb 27, 2024; 16(2): 571-584
Published online Feb 27, 2024. doi: 10.4240/wjgs.v16.i2.571

Full Size Figure Download Figure

Figure 2 Network plot of included studies of proactive therapeutic drug monitoring vs conventional management with available direct comparisons for clinical remission. IFX: Infliximab; ADA: Adalimumab; IFX: Infliximab; CD: Crohn's disease; RCT: Randomized controlled trial; UC: Ulcerative colitis; IBD: Inflammatory bowel disease.

Citation: Zheng FY, Yang KS, Min WC, Li XZ, Xing Y, Wang S, Zhang YS, Zhao QC. Is tumor necrosis factor-α monoclonal therapy with proactive therapeutic drug monitoring optimized for inflammatory bowel disease? Network meta-analysis. World J Gastrointest Surg 2024; 16(2): 571-584
URL: https://www.wjgnet.com/1948-9366/full/v16/i2/571.htm
DOI: https://dx.doi.org/10.4240/wjgs.v16.i2.571